Collegium (NASDAQ: COLL) EVP sells 6,224 shares under 10b5-1 plan

Rhea-AI Filing Summary

Collegium Pharmaceutical EVP & General Counsel David Dieter sold 6,224 shares of common stock at $36.65 per share in an open-market transaction. After this sale, he directly holds 91,047 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was scheduled in advance rather than timed discretionarily.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dieter David

(Last) (First) (Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON MA 02072

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		S(1)		6,224	D	$36.65	91,047	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

	/s/ Colleen Tupper as Attorney-In-Fact For Scott Dreyer	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did COLLEGIUM PHARMACEUTICAL (COLL) report for David Dieter?

Collegium Pharmaceutical reported that EVP & General Counsel David Dieter sold 6,224 shares of common stock at $36.65 per share. The sale was an open-market transaction and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025.

How many COLLEGIUM PHARMACEUTICAL (COLL) shares does David Dieter hold after this Form 4 sale?

Following the reported sale, David Dieter directly holds 91,047 shares of Collegium Pharmaceutical common stock. This filing shows his position after the 6,224-share open-market transaction, giving investors context on his remaining ownership stake in the company.

Was the COLLEGIUM PHARMACEUTICAL (COLL) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by David Dieter on December 5, 2025. Such plans pre-schedule trades, which can reduce the significance of the sale’s specific timing for investors.

What price did David Dieter receive per share in the COLLEGIUM PHARMACEUTICAL (COLL) sale?

David Dieter sold his Collegium Pharmaceutical common stock at an average price of $36.65 per share. This price reflects the execution level disclosed in the Form 4 for the 6,224 shares sold in the open-market transaction on March 9, 2026.

What type of transaction is reported in COLLEGIUM PHARMACEUTICAL (COLL) latest Form 4?

The filing reports an open-market sale of common stock by an executive officer. The transaction code is “S,” indicating a sale, and it involves 6,224 shares sold at $36.65 each, with post-transaction direct holdings of 91,047 shares.

Does the COLLEGIUM PHARMACEUTICAL (COLL) Form 4 involve any derivative securities?

No. The reported transaction involves only non-derivative common stock. The derivative summary section is empty, indicating no options, warrants, or other derivative securities were exercised, converted, or otherwise transacted in this particular Form 4 filing.